2018 Q2 Form 10-Q Financial Statement
#000156459018018096 Filed on July 31, 2018
Income Statement
| Concept | 2018 Q2 | 2017 Q4 | 2017 Q2 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $5.900M | $4.900M | $1.700M |
| YoY Change | 247.06% | 345.45% | |
| % of Gross Profit | |||
| Research & Development | $27.54M | $13.10M | $10.42M |
| YoY Change | 164.22% | 133.93% | |
| % of Gross Profit | |||
| Depreciation & Amortization | |||
| YoY Change | |||
| % of Gross Profit | |||
| Operating Expenses | $27.54M | $18.00M | $10.42M |
| YoY Change | 164.22% | 168.66% | |
| Operating Profit | -$33.49M | -$17.99M | -$12.13M |
| YoY Change | 176.0% | 188.02% | 60.21% |
| Interest Expense | $184.0K | -$300.0K | $5.854K |
| YoY Change | 3043.3% | ||
| % of Operating Profit | |||
| Other Income/Expense, Net | -$32.87K | $0.00 | $397.00 |
| YoY Change | -8378.84% | -100.0% | |
| Pretax Income | -$33.30M | -$18.30M | -$12.10M |
| YoY Change | 175.21% | 177.27% | |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$33.33M | -$18.26M | -$12.13M |
| YoY Change | 174.9% | 175.76% | 66.24% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$608.8K | -$371.2K | -$245.4K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 50.33M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q2 | 2017 Q4 | 2017 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $253.8M | $175.6M | $4.900M |
| YoY Change | 5079.59% | 605.22% | |
| Cash & Equivalents | $253.8M | $175.6M | $4.939M |
| Short-Term Investments | |||
| Other Short-Term Assets | $7.695K | $14.82K | $2.600M |
| YoY Change | -99.7% | -40.71% | |
| Inventory | |||
| Prepaid Expenses | $10.86M | $5.060M | |
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $266.7M | $182.0M | $9.300M |
| YoY Change | 2767.76% | 565.05% | |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | |||
| YoY Change | |||
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $116.2K | $116.2K | $100.0K |
| YoY Change | 16.15% | 80.0% | |
| Total Long-Term Assets | $116.2K | $116.2K | $100.0K |
| YoY Change | 16.15% | 80.0% | |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $266.7M | $182.0M | $9.300M |
| Total Long-Term Assets | $116.2K | $116.2K | $100.0K |
| Total Assets | $266.8M | $182.1M | $9.400M |
| YoY Change | 2738.49% | 563.91% | |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $5.133M | $3.663M | $2.600M |
| YoY Change | 97.42% | 43.81% | |
| Accrued Expenses | $5.121M | $2.891M | $3.500M |
| YoY Change | 46.32% | 164.78% | |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $10.25M | $6.554M | $6.100M |
| YoY Change | 68.1% | 80.11% | |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $26.80M | $26.40M | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $300.0K | $200.0K | |
| YoY Change | |||
| Total Long-Term Liabilities | $27.10M | $26.60M | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $10.25M | $6.554M | $6.100M |
| Total Long-Term Liabilities | $27.10M | $26.60M | $0.00 |
| Total Liabilities | $37.30M | $33.19M | $6.100M |
| YoY Change | 511.48% | 812.04% | |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$204.3M | -$149.3M | |
| YoY Change | 51.91% | ||
| Common Stock | $5.615K | $5.033K | |
| YoY Change | 497.03% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $229.6M | $148.9M | $3.300M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $266.8M | $182.1M | $9.400M |
| YoY Change | 2738.49% | 563.91% |
Cashflow Statement
| Concept | 2018 Q2 | 2017 Q4 | 2017 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$33.33M | -$18.26M | -$12.13M |
| YoY Change | 174.9% | 175.76% | 66.24% |
| Depreciation, Depletion And Amortization | |||
| YoY Change | |||
| Cash From Operating Activities | -$30.69M | -$15.54M | -$11.49M |
| YoY Change | 167.1% | 137.61% | -11.27% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | |||
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | |||
| YoY Change | |||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 131.6M | 178.1M | 0.000 |
| YoY Change | -100.0% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -30.69M | -15.54M | -11.49M |
| Cash From Investing Activities | |||
| Cash From Financing Activities | 131.6M | 178.1M | 0.000 |
| Net Change In Cash | 100.9M | 162.5M | -11.49M |
| YoY Change | -978.33% | -2584.86% | -701.57% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$30.69M | -$15.54M | -$11.49M |
| Capital Expenditures | |||
| Free Cash Flow | |||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q2 | us-gaap |
Assets Current
AssetsCurrent
|
266701518 | |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
116150 | |
| CY2018Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
116150 | |
| CY2017Q4 | us-gaap |
Assets
Assets
|
182131456 | |
| CY2018Q2 | us-gaap |
Long Term Line Of Credit
LongTermLineOfCredit
|
20143217 | |
| CY2018Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2017Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
14823 | |
| CY2017Q4 | apls |
Common Stock Warrant Liability Noncurrent
CommonStockWarrantLiabilityNoncurrent
|
244292 | |
| CY2018Q2 | apls |
Common Stock Warrant Liability Noncurrent
CommonStockWarrantLiabilityNoncurrent
|
250000 | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
175643529 | |
| CY2017Q4 | apls |
Refundable Research And Development Credit Current
RefundableResearchAndDevelopmentCreditCurrent
|
1297361 | |
| CY2018Q2 | apls |
Refundable Research And Development Credit Current
RefundableResearchAndDevelopmentCreditCurrent
|
1996996 | |
| CY2017Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
5059593 | |
| CY2018Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
10857287 | |
| CY2018Q2 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
6618150 | |
| CY2018Q2 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
7695 | |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
182015306 | |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
298201480 | |
| CY2018Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10254195 | |
| CY2017Q4 | us-gaap |
Long Term Line Of Credit
LongTermLineOfCredit
|
19806944 | |
| CY2018Q2 | us-gaap |
Assets
Assets
|
266817668 | |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3663253 | |
| CY2018Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5133017 | |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2890705 | |
| CY2018Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5121178 | |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
6553958 | |
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2017Q4 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
6583402 | |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
5033 | |
| CY2018Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
5615 | |
| CY2018Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
433880750 | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-149263653 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
44940509 | ||
| CY2018Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-204334259 | |
| CY2018Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2018Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
56154438 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
17653143 | ||
| CY2018Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5947823 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3531753 | ||
| CY2018Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
253839540 | |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
33188596 | |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
182131456 | |
| CY2017Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
10422059 | |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
148942860 | |
| CY2018Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
229552106 | |
| CY2018Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
266817668 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
50334152 | |
| CY2018Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2018Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
50334152 | |
| CY2018Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
56154438 | |
| CY2018Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
27537619 | |
| CY2018Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2018Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2018Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2017Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1710344 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9983079 | ||
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12132403 | |
| CY2017Q2 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
5854 | |
| CY2018Q2 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
184009 | |
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
15966 | ||
| CY2017Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
397 | |
| CY2018Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-32867 | |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-7995 | ||
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12126152 | |
| CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-33334300 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-21176925 | ||
| CY2017Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.44 | |
| CY2018Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.61 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.51 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.05 | ||
| CY2017Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
8428366 | |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
54691833 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
8428366 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
52534806 | ||
| us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
131325027 | ||
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
501110 | ||
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3853715 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
708833 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3853715 | ||
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
5708 | ||
| us-gaap |
Accretion Expense
AccretionExpense
|
34748 | ||
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
336273 | ||
| us-gaap |
Income Tax Credits And Adjustments
IncomeTaxCreditsAndAdjustments
|
-416412 | ||
| us-gaap |
Income Tax Credits And Adjustments
IncomeTaxCreditsAndAdjustments
|
-699635 | ||
| us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
1457696 | ||
| us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
5797694 | ||
| us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-7128 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
61632 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
57186 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1469764 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
2422245 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
2230473 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19924401 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-53630126 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
131325027 | ||
| us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
The Company effectuated a l-for-2.133 reverse stock split of its outstanding common stock, which was approved by the Company’s board of directors on October 27, 2017. | ||
| CY2017Q4 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.468823254 | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
501110 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
131826137 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-19924401 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
78196011 | ||
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
24863488 | |
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4939087 | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Organization and Operations </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Apellis Pharmaceuticals, Inc. (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was incorporated in September 2009 under the laws of the State of Delaware and has its principal office in Crestwood, Kentucky. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital and developing its product candidates. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”). </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity and Financial Condition </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of July 31, 2018, the date of issuance of these unaudited condensed consolidated financial statements, the Company believes that its cash and cash equivalents as of June 30, 2018 of $253.8 million will be sufficient to fund its operations for at least twelve months into the third quarter of 2019. The future viability beyond that point is dependent on its ability to raise additional capital to finance its operations.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to other life science companies in the development stage including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with FDA and other government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability. Management’s plans in order to meet its short-term and longer term operating cash flow requirements include obtaining additional funding. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are uncertainties associated with the Company’s ability to (1) obtain additional debt or equity financing (2) enter into collaborative agreements with strategic partners, and (3) succeed in its future operations. If the Company is not able to obtain the required capital to fund its operations from any of these, or is not able to obtain such funding on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts and its business could be materially harmed. </p></div> | ||
| CY2017Q4 | apls |
Reverse Stock Split Date
ReverseStockSplitDate
|
2017-10-27 | |
| CY2017Q4 | us-gaap |
Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
|
30070034 | |
| CY2017Q4 | apls |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
2463808 | |
| CY2018Q2 | apls |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
3478400 | |
| CY2018Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
180859 | |
| CY2018Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
1666667 | |
| CY2018Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
10000000 | |
| CY2018Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
8333333 | |
| CY2017Q4 | apls |
Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
|
251491 | |
| CY2018Q2 | apls |
Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
|
1461919 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
175406 | |
| CY2018Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
|
7000000 | |
| CY2018Q2 | us-gaap |
Long Term Debt
LongTermDebt
|
27000000 | |
| CY2018Q2 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | |
| CY2017Q2 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | |
| CY2018Q2 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | |
| CY2017Q2 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | |
| CY2017Q4 | apls |
Tax Cuts And Jobs Act Of2017 Re Measurement Of Deferred Taxes
TaxCutsAndJobsActOf2017ReMeasurementOfDeferredTaxes
|
16000000 | |
| CY2018Q2 | apls |
Remaining Contract Costs
RemainingContractCosts
|
1162000 | |
| CY2017Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
31092014 | |
| CY2018Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7307400 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
31092014 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7307400 |
